NEFL and Alzheimer disease: The results revealed a trend for gradually increasing expression of plasma GFAP, NfL, and p-tau181 from normal cognitive function to MCI and AD, especially in the AD phase, which was associated with a significantly upregulated expression of these plasma biomarkers.